Overview

Gaucher Disease Treatment Market is poised to value over USD 2.4 billion during the forecast period 2022 to 2028.

Gaucher disease is an inherited, rare condition. The condition pertains to lipid metabolism. There is not enough of an enzyme called glucocerebrosidase if you have it. The result is that too much fatty substance builds up in the spleen, liver, lungs, bones, and even the brain. As a consequence, these organs are unable to function normally. 

After starting treatment with enzyme replacement therapy, miglustat (Zavesca), elglustat (Cerdelga), and osteoporosis drugs, many people suffering from Gaucher disease have seen improvements in their symptoms. The doctor might recommend a bone marrow transplant or splenectomy if your symptoms are too severe for less invasive treatments.

In recent years, the US Food and Drug Administration (FDA) has authorised a number of medications for illness treatment. Vpriv (velaglucerase alfa) was licenced by the FDA in 2010 as an enzyme replacement therapy (ERT) for type 1 Gaucher disease. Elelyso (taliglucerase alfa) and Cerdelga (eliglustat) were authorised by the FDA in 2012 and 2014, respectively, for type 1 Gaucher disease. These medications provide a choice of solutions based on individual needs, which is projected to drive market expansion.

The European Therapies Agency (EMA) and the US Food and Drug Administration (FDA) cooperated in July 2017 to encourage the adoption of novel techniques in the development of Gaucher disease medicines.

It is the most prevalent lysosomal storage disease, with a prevalence of 1 in every 50,000 live births. The perinatal fatal type of the illness is the most severe. Gaucher illness is thought to present itself most strongly in the Jewish community of Eastern and Central Europe, affecting 1 out of every 450 persons and 1 out of every 10 disease carriers within the descend. Increased medical progress in rare condition research and development is raising awareness and may eventually lead to a cure.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Gaucher Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Gaucher Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Gaucher Disease Treatment Market:
• Abbott
• Aptalis Pharma
• Genzyme Corporation
• GlaxoSmithKline (GSK)
• Pfizer Inc.
• Shire Human Genetic Therapies, Inc.
• Eli Lilly and Company
• Enobia Pharma Inc.
• Anthera Pharmaceuticals, Inc.
• BioMarin Pharmaceutical Inc.
• MedPro Rx
• Zymenex A/S
• Merck Serono
(Note: The list of the major players will be updated with the latest market scenario and trends)

Gaucher Disease Treatment Market Segmentation:
By Disease Type
• Type 1 (Neuropathic Forms)
• Type 2 (Perinatal Lethal Form)
• Type 3 (Slow-Neurologic Decay Form)

By Medication  
• Enzyme replacement therapy (ERT)
  o Imiglucerase (Cerezyme)
  o Velaglucerase alfa (VPRIV)
  o Taliglucerase alfa (Elelyso)
  o Others
• Substrate reduction therapy (SRT)
  o Glucosylceramide synthase inhibitors
       o Miglustat
       o Eliglustat
• Surgical
   o Bone marrow transplant
   o Spleen Removal

By End User
• Hospitals  
• Ambulatory Surgical Centers
• Clinical research institutes

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Gaucher Disease Treatment Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Gaucher Disease Treatment Market By Disease Type, By Medication, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Gaucher Disease Treatment Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Gaucher Disease Treatment Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Gaucher Disease Treatment Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Gaucher Disease Treatment Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Type 1 (Neuropathic Forms)
   7.2. Type 2 (Perinatal Lethal Form)
   7.3. Type 3 (Slow-Neurologic Decay Form)

8. Gaucher Disease Treatment Market, By Medication Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Enzyme replacement therapy (ERT)
        8.1.1. Imiglucerase (Cerezyme)
        8.1.2. Velaglucerase alfa (VPRIV)
        8.1.3. Taliglucerase alfa (Elelyso)
        8.1.4. Others
   8.2. Substrate reduction therapy (SRT)
        8.2.1. Glucosylceramide synthase inhibitors
               8.2.1.1. Miglustat
               8.2.1.2. Eliglustat
   8.3. Surgical
        8.3.1. Bone marrow transplant
        8.3.2. Spleen Removal

9. Gaucher Disease Treatment Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospitals  
   9.2. Ambulatory Surgical Centers
   9.3. Clinical research institutes

10. North America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Gaucher Disease Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Abbott
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Aptalis Pharma
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Genzyme Corporation
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. GlaxoSmithKline (GSK)
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Pfizer Inc.
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Shire Human Genetic Therapies, Inc.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. Eli Lilly and Company
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Enobia Pharma Inc.
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Anthera Pharmaceuticals, Inc.
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.BioMarin Pharmaceutical Inc.
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview
    16.11.MedPro Rx
          16.11.1. Company Overview
          16.11.2. Product Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview          
    16.12.Zymenex A/S
          16.12.1. Company Overview
          16.12.2. Product Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview      
    16.13.Merck Serono
          16.13.1. Company Overview
          16.13.2. Product Portfolio
          16.13.3. SWOT Analysis
          16.13.4. Financial Overview
          16.13.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures